Aqualung Therapeutics Receives FDA Clearance for Phase 2a Lung Fibrosis Study - December 5, 2025
Read More

Aqualung Therapeutics Receives NIH STTR Grant Award $1.2M to develop ALT-100 mAb for Progressive Pulmonary Fibrosis - September 15, 2025
Read More

Acute Respiratory Distress Syndrome (ARDS) Aqualung Therapeutics Appoints Two New Board Directors - June 2022
Read Press Release

Predictive Medicine, Biomarkers & the Multiple Unmet Needs in Acute Respiratory Distress Syndrome - April 2022
Read Article

Aqualung Therapeutic's ALT-100 Monoclonal Antibody Cited as A Novel Therapeutic for Lung Fibrosis - April 2022
Read Press Release

Tucson startup looks to human trials for drug to treat lung inflammation - March 2022
Read Article

Aqualung Therapeutic’s ALT-100 Antibody Significantly Reduces ARDS Severity in Both Rat and Porcine (Large Animal) Preclinical Models - Feb 2022
Read Press Release

Aqualung Therapeutics Corp., an Immunotherapeutics Biotech Company, Closes a $2.5M Convertible Note Raise With a Committed Series A Lead Investor- January 2022
Read Press Release

Tucson startup looks to human trials for drug to treat lung inflammation - January 2022
Read Article

CEO & Founder of Aqualung Therapeutics Corp., Joe G.N. Garcia MD to Present Corporate Update at the Annual Biotech Showcase - December 2021
Read Press Release

Dr. Joe GN Garcia speaks on the impacts of COVID-19 in the year 2020 in PharmaVOICE Magazine Nov/Dec Issue - Nov / Dec 2021
Read Article

Aqualung Therapeutics Selected to Present at the Phoenix 2021 Venture Madness Competition - August 2021
Read Press Release

Dr. Garcia Grand Rounds at Houston Methodist - July 2021
Watch Video

CEO of Aqualung Therapeutics Corp., Joe G.N. Garcia MD, Named Invited Speaker at the First Annual Acute Respiratory Distress Syndrome Drug Development Summit - June 2021
Read Press Release

Aqualung Therapeutics Plans A Phase 0 ARDS Trial for eNAMPT Monoclonal Antibody (Alt-100 mAb) Following Type B FDA Meeting - June 2021
Read Press Release

eNAMPT, an inflammation-regulatory protein is now tightly linked to COVID-19 deaths - Feb 2021
Read Article

Studies: eNAMPT, an inflammation-regulatory protein is now tightly linked to COVID-19 deaths - Feb 2021
Read Article

Aqualung Therapeutics Corp. Awarded $300 Thousand From National Institute of Health (NIH) to Develop a Novel Therapeutic for Pregnant Women at Risk for Preterm Births - September 2020
Read Press Release

Dr. Joe GN Garcia addresses the Foe Behind Covid-19 Deaths: Acute Respiratory Distress Syndrome - July 2020
Listen to Interview

Healing lungs, improving data, oncology research and more - June 2020
Read Article

Why An Experimental Therapy for Inflammatory Disorders Could Help the Fight Against COVID-19 - May 2020
Play Podcast

Aqualung Therapeutics Corp. Receives NIH Approval to Advance to IND-Enabling Studies Via the STTR Fastrack Phase II Award for Development of A Novel Anti-Inflammatory Therapeutic Antibody for ARDS - May 2020
Read Press Release

Aqualung Takes Genomic Approach to COVID-19’s Killer Lung Inflammation - April 2020
Read Article

Deaths with COVID-19 primarily in patients transferred to ICU – KGUN9 Interview - April 2020
Watch Video

Fight Against COVID 19 May Yield Solutions to ARDS - April 2020
Read Article